Investors

Making human cell models more predictive, without making them harder to use.

Scalable, flow-enabled Transwell assays for pharma — starting with intestinal permeability.

Updated November 2026

The problem

Why today’s assays fall short for the compounds pharma works with now

Static Transwells struggle with hard compounds

Low-permeability and poorly soluble candidates yield weak signals and less reliable data in standard static Caco-2 setups.

Complex chips don’t scale for discovery

More predictive dynamic systems often need pumps, tubing and specialised workflows discovery teams cannot run routinely.

The missing middle

Pharma needs physiological flow inside the familiar plate workflow — not a replacement of their assay infrastructure.

Evidence

Beyond the academic prototype

A working technological principle, early biological signals and first commercial traction — with validation still underway.

Technology

  • Working system in a standard incubator
  • Scalable 24-well architecture
  • Long-term incubator operation

Biology

  • Flow-induced biological effects observed
  • Faster Caco-2 differentiation — early signal
  • Permeability benchmark ongoing with partners

Commercial

  • Paid pilots
  • Pharma and CRO engagement
  • Prototype customer activity

Early partners

  • Erasmus MC
  • University of Galway
The platform

Better biology, familiar workflow

MACplate + MACnet bring controlled physiological flow into a standard Transwell workflow — without pumps or tubing. Teams keep their inserts, dosing, sampling and read-outs.

Protected magnetic-cilia know-how, spun out of Eindhoven University of Technology.

See FlowGUT — our beachhead assay
ARTIC MACplate
Expansion

Beachhead first. Platform next.

Focused for a seed round — with a clear path to venture scale.

  1. 01

    FlowGUT

    Intestinal permeability beachhead

  2. 02

    Pharma ADME

    Routine discovery assays

  3. 03

    Barrier & immune

    More applications, same plate

  4. 04

    96-well

    Higher throughput next

Commercialisation

How we sell

Instrument + recurring consumables

MACnet actuation (illustrative ~€20k) with recurring MACplate consumables — a tools model discovery labs already understand.

  1. Pharma discovery

    Beachhead where permeability pain is acute.

  2. Selected pilots

    Paying pharma and CRO partners.

  3. Product launch

    Routine-ready 24-well system.

  4. CROs & scale

    Broader screening through service labs.

The round

What the seed unlocks

Today

Working principle, first traction, product and biological validation underway.

Seed

Productise 24-well, robust benchmark, 2–3 pharma pilots, 96-well development, manufacturing scale-up.

Series A ready

A product pharma can use routinely — with evidence and a clear scale path.

Why ARTIC

Why ARTIC can win

  • Team spanning MPS R&D, biology applications and life-sciences go-to-market
  • TU/e origin in artificial cilia, with protected platform know-how
  • Non-dilutive grants as capital leverage — customer traction is the validation
  • Laure van der Sanden
    Laure van der Sanden
    CEO, co-founder
    MSc Innovation Sciences · BD & scale-up
  • Dr. Hossein Amirabadi
    Dr. Hossein Amirabadi
    CTO, co-founder
    13y+ MPS R&D · Board member 3RsC
  • Prof. Jaap den Toonder
    Prof. Jaap den Toonder
    Science · co-founder
    Artificial cilia pioneer · TU/e
  • Sander de Vos
    Sander de Vos
    Business Advisor
    Former Sales Director, Mimetas

Origin & partners

  • Eindhoven University of Technology
  • Brabantse Ontwikkelings Maatschappij
  • Brabant Startup Fonds
  • Rabobank
  • NWO
  • Co-funded by the European Union

Preparing

€3M

seed round

Preparing a €3M seed round

Seeking life sciences investors with expertise in tools, preclinical R&D or drug discovery.

Prefer a conversation? Reach out after requesting the deck.

Laure van der Sanden

Request the investor deck

Name, work email and fund or company. We review every request and share the deck by email.

We review every request and reply by email.